← All countries · Europe
94%
MCV1
2025 · WHO/UNICEF estimate
96%
DTP3
2025 · WHO/UNICEF estimate
96%
IPV complete
2025 · WHO/UNICEF estimate
12
Measles cases
2025 reported
427
Pertussis (whooping cough) cases
2025 reported
Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.
Vaccination coverage
| Vaccine | Latest estimate | Country-reported | Trend since 2000 | Data quality |
|---|---|---|---|---|
| BCGTuberculosis vaccine at birth | 85%1984 · Administrative (country-reported) | 85% | too few points | D · poor |
| DTP1First dose of diphtheria-tetanus-pertussis | 97%2025 · WHO/UNICEF estimate | 96.8% | A · strong | |
| DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme) | 96%2025 · WHO/UNICEF estimate | 96.2% | A · strong | |
| IPV1First dose of inactivated polio vaccine | 97%2025 · WHO/UNICEF estimate | 96.8% | A · strong | |
| IPV completeInactivated polio vaccine, complete primary series | 96%2025 · WHO/UNICEF estimate | 96.2% | C · weak | |
| MCV1First dose of measles-containing vaccine | 94%2025 · WHO/UNICEF estimate | 94.1% | A · strong | |
| MCV2Second dose of measles-containing vaccine | 94%2025 · WHO/UNICEF estimate | 93.8% | A · strong | |
| RCV1First dose of rubella-containing vaccine | 94%2025 · WHO/UNICEF estimate | 94.1% | A · strong | |
| HepB3Third dose of hepatitis B vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| HepB birthHepatitis B birth dose within 24 hours | —% · Administrative (country-reported) | — | too few points | no data |
| Hib3Third dose of Haemophilus influenzae type b vaccine | 96%2025 · WHO/UNICEF estimate | 96.2% | A · strong | |
| PCV1Pneumococcal conjugate vaccine, first dose | 96.6%2025 · Administrative (country-reported) | 96.6% | D · poor | |
| PCV completePneumococcal conjugate vaccine, final dose of the schedule | 96%2025 · WHO/UNICEF estimate | 95.9% | A · strong | |
| RotaCRotavirus vaccine, complete series | —% · Administrative (country-reported) | — | too few points | no data |
| Yellow feverYellow fever vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| MenAMeningococcal A conjugate (meningitis belt) | —% · Administrative (country-reported) | — | too few points | no data |
| JEJapanese encephalitis vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| TCVTyphoid conjugate vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| PABProtection at birth against neonatal tetanus (maternal tetanus doses) | —% · Administrative (country-reported) | — | too few points | no data |
| HPV dose 1, girlsHPV programme coverage, first dose, girls | 90%2025 · WHO/UNICEF estimate | — | B · good | |
| HPV complete, girlsHPV programme coverage, complete series, girls | 82%2025 · WHO/UNICEF estimate | — | B · good | |
| HPV dose 1, boysHPV programme coverage, first dose, boys | 88%2025 · WHO/UNICEF estimate | — | D · poor |
Reported vaccine-preventable disease
| Disease | Reported cases | Incidence rate | Trend since 2000 | Data quality |
|---|---|---|---|---|
| Measles all countries · vaccine evidence | 122025 | 2per 1,000,000 total population | A · strong | |
| Rubella all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Congenital rubella syndrome all countries · vaccine evidence | 02025 | 0per 10,000 live births | B · good | |
| Mumps all countries · vaccine evidence | 32025 | 0.5per 1,000,000 total population | A · strong | |
| Pertussis (whooping cough) all countries · vaccine evidence | 4272025 | 71.1per 1,000,000 total population | A · strong | |
| Diphtheria all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Tetanus (total) all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Neonatal tetanus all countries · vaccine evidence | 02025 | 0per 1,000 live births | C · weak | |
| Polio (paralytic) all countries · vaccine evidence | 02021 | 0per 1,000,000 <15 population | D · poor | |
| Yellow fever all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Japanese encephalitis all countries · vaccine evidence | 02021 | 0per 1,000,000 total population | D · poor | |
| Invasive meningococcal disease all countries · vaccine evidence | 322025 | 5.3per 1,000,000 total population | C · weak | |
| Typhoid all countries · vaccine evidence | 132025 | 2.2per 1,000,000 total population | B · good |
National schedule (latest WHO listing)
Show the schedule (43 rows)
| Vaccine | Dose | Age | Target group | Comment |
|---|---|---|---|---|
| COVID19COVID-19 vaccine | 1 | Adults | All older adults | |
| COVID19COVID-19 vaccine | 1 | Risk group(s) | Children and adolescents with chronic conditions, adults with chronic conditions, older adults with chronic conditions, other groups | |
| DTAPHIBIPVDTaP-Hib-IPV (acellular) vaccine | 1 | M3 | General/routine | |
| DTAPHIBIPVDTaP-Hib-IPV (acellular) vaccine | 2 | M5 | General/routine | |
| DTAPHIBIPVDTaP-Hib-IPV (acellular) vaccine | 3 | M12 | General/routine | |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | 1st contact | Risk group(s) | risk groups (lives in a household with or is a sexual partner of a person with chronic hepatitis b, IV abuser, people with hepatitis C, down syndrome and others) |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 2 | +M1 | Risk group(s) | risk groups (lives in a household with or is a sexual partner of a person with chronic hepatitis b, IV abuser, people with hepatitis C, down syndrome and others) |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 3 | +M6 | Risk group(s) | risk groups (lives in a household with or is a sexual partner of a person with chronic hepatitis b, IV abuser, people with hepatitis C, down syndrome and others) |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 1 | B | Risk group(s) | Neonates of HBsAG positive mothers |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 2 | M1 | Risk group(s) | Neonates of HBsAG positive mothers |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 3 | M2 | Risk group(s) | Neonates of HBsAG positive mothers |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 4 | M12 | Risk group(s) | Neonates of HBsAG positive mothers |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 1 | <=Y18 | Catch-up children | Only females up until August 2019. From September 2019 HPV-programme expanded to cover males born after July 2007 - 1st dose between Y12-Y14, second dose more than +M5 but less than +M13 (free vaccination up to the age of 18). |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 1 | Y12-Y14 | HPV administered to females and males | Only females up until August 2019. From September 2019 HPV-programme expanded to cover males born after July 2007 - 1st dose between Y12-Y14, second dose more than +M5 but less than +M13 (free vaccination up to the age of 18). |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 2 | +M5-M13 | HPV administered to females and males | Only females up until August 2019. From September 2019 HPV-programme expanded to cover males born after July 2007 - 1st dose between Y12-Y14, second dose more than +M5 but less than +M13 (free vaccination up to the age of 18). |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | >=Y65 | Adults | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Pregnant women | Pregnant women | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Risk group(s) | Adults with chronic conditions, residents living in long-term care facilities, other groups | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | Risk group(s) | Children with chronic conditions | |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | M15 | General/routine | |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | >=Y18 | Risk group(s) | Recommended for all non-immune adults. Free of charge from April 1, 2018 Women of childbearing age not immune to Rubella demonstrated by antibody measurement. Given in the form of a single MFR |
| MMRMMR (Measles, mumps and rubella) vaccine | 2 | Y4 | General/routine | |
| MPOXMpox (monkeypox) vaccine | 1 | 1st contact | Risk group(s) | MSM who have had protected or unprotected sexual contact with at least two male partners within the past 12 weeks. MSM who have had a sexually transmitted infection within the past 24 weeks. Women, transgender, non-binary or other individuals who, based on an individual medical assessment using the above criteria, are considered at increased risk of infection. Individuals traveling to areas with outbreaks of mpox clade Ia and/or Ib who, following a specialist infectious disease assessment, are considered at particular risk of exposure, for example healthcare workers or those working in refugee camps or humanitarian aid. |
| MPOXMpox (monkeypox) vaccine | 1 | 1st contact | Travellers | MSM who have had protected or unprotected sexual contact with at least two male partners within the past 12 weeks. MSM who have had a sexually transmitted infection within the past 24 weeks. Women, transgender, non-binary or other individuals who, based on an individual medical assessment using the above criteria, are considered at increased risk of infection. Individuals traveling to areas with outbreaks of mpox clade Ia and/or Ib who, following a specialist infectious disease assessment, are considered at particular risk of exposure, for example healthcare workers or those working in refugee camps or humanitarian aid. |
| MPOXMpox (monkeypox) vaccine | 2 | +D28 | Risk group(s) | MSM who have had protected or unprotected sexual contact with at least two male partners within the past 12 weeks. MSM who have had a sexually transmitted infection within the past 24 weeks. Women, transgender, non-binary or other individuals who, based on an individual medical assessment using the above criteria, are considered at increased risk of infection. Individuals traveling to areas with outbreaks of mpox clade Ia and/or Ib who, following a specialist infectious disease assessment, are considered at particular risk of exposure, for example healthcare workers or those working in refugee camps or humanitarian aid. |
| MPOXMpox (monkeypox) vaccine | 2 | +D28 | Travellers | MSM who have had protected or unprotected sexual contact with at least two male partners within the past 12 weeks. MSM who have had a sexually transmitted infection within the past 24 weeks. Women, transgender, non-binary or other individuals who, based on an individual medical assessment using the above criteria, are considered at increased risk of infection. Individuals traveling to areas with outbreaks of mpox clade Ia and/or Ib who, following a specialist infectious disease assessment, are considered at particular risk of exposure, for example healthcare workers or those working in refugee camps or humanitarian aid. |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 1 | M3 | General/routine | From 1 November 2025, the pneumococcal vaccine in the childhood immunization programme changed from PCV-13 to PCV-15. |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 1 | 1st contact | Risk group(s) | Has previously been used for Risk groups. Not for free but with a smaller co-payment. In 2025 PCV-20/PCV-21 is primarily used for risk groups. |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 2 | M5 | General/routine | From 1 November 2025, the pneumococcal vaccine in the childhood immunization programme changed from PCV-13 to PCV-15. |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 3 | M12 | General/routine | From 1 November 2025, the pneumococcal vaccine in the childhood immunization programme changed from PCV-13 to PCV-15. |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 1 | 1st contact | Risk group(s) | Can be used for Risk groups Not for free but a smaller co-payment |
| PCV_15_VALENTPCV-15 (Pneumococcal conjugate vaccine 15-valent) vaccine | 1 | M3 | General/routine | From 1 November 2025, the pneumococcal vaccine in the childhood immunization programme changed from PCV-13 to PCV-15 |
| PCV_15_VALENTPCV-15 (Pneumococcal conjugate vaccine 15-valent) vaccine | 2 | M5 | General/routine | From 1 November 2025, the pneumococcal vaccine in the childhood immunization programme changed from PCV-13 to PCV-15 |
| PCV_15_VALENTPCV-15 (Pneumococcal conjugate vaccine 15-valent) vaccine | 3 | M12 | General/routine | From 1 November 2025, the pneumococcal vaccine in the childhood immunization programme changed from PCV-13 to PCV-15 |
| PCV_21_VALENTPCV-21 (Pneumococcal conjugate vaccine 21-valent) vaccine | 1 | 1st contact | Risk group(s) | Can be used for Risk groups. Not for free but a smaller co-payment |
| PPV23PPV-23 (Pneumococcal polysaccharide 23-valent) vaccine | 1 | 1st contact | Risk group(s) | In 2025 patients in certain groups could be vaccinated either with PPV-23 or PCV-20 or PCV-21- not for free but with a smaller co-payment. |
| PPV23PPV-23 (Pneumococcal polysaccharide 23-valent) vaccine | 2 | +Y6 | Risk group(s) | In 2025 patients in certain groups could be vaccinated either with PPV-23 or PCV-20 or PCV-21- not for free but with a smaller co-payment. |
| RSVRSV (Respiratory syncytial virus) vaccine | 1 | Pregnant women | Pregnant women at gestational weeks 32–36 were offered vaccination against RSV from october 1, 2025 until january 31, 2026 | |
| RSVRSV (Respiratory syncytial virus) vaccine | 1 | Risk group(s) | Persons aged 60 years and older with COPD can be vaccinated with a smaller co-payment | |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 1 | Pregnant women | From 1.1 2024 Tdap has been a permanent offer for pregnant woman. Tdap is recommended in gestational week 25, earlier in cases of risk of preterm birth. in their 2rd or 3rd trimester. | |
| TDAP_S_IPVTdap-IPV (Tetanus, diphtheria for older children and adults, acellular pertussis and IPV) vaccine | 4 | Y5 | General/routine | |
| ZOSTERShingles (Herpes zoster for older adults) vaccine | 1 | 1st contact | Risk group(s) | Not for free but Subsidies are granted to persons aged 18 years and older with immunosuppression, either as a result of medical treatment (planned or ongoing) or due to congenital or acquired diseases and conditions |
| ZOSTERShingles (Herpes zoster for older adults) vaccine | 2 | +M2 | Risk group(s) | Not for free but Subsidies are granted to persons aged 18 years and older with immunosuppression, either as a result of medical treatment (planned or ongoing) or due to congenital or acquired diseases and conditions |
Compare schedules across 31 countries on the schedule hub.
Data and sources
- Download this country's data (JSON): every year, every antigen and disease, with the grade reasons.
- Coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and country-reported administrative/official coverage, from the WHO Immunization Data Portal export downloaded 21 October 2026.
- Reported cases and incidence: WHO/UNICEF Joint Reporting Form, same export. Incidence denominators are stated per row.
- Schedule: WHO vaccine-schedule export, latest listing year.